BGM Group Ltd.
BGM · Price history
Price at last available close
$8.75
+$1.28 (+17.14%) 1M
2026-10-29
Tap or drag sideways to inspect a price. Use two fingers to compare automatically. Release to scroll. Use Shift + arrow keys to compare with a keyboard.
Company & revenue
About BGM Group Ltd.
Primary reporting period: 2025-09-30 · Research updated Oct 12, 2026. A research update is not a new financial filing.
Who they are
Operating from Chengdu, People's Republic of China, BGM Group Ltd. engages in the manufacturing and supply of active pharmaceutical ingredients (APIs), traditional Chinese medicine (TCM) derivatives, and various other related products across China. The company's pharmaceutical portfolio includes an array of licorice-based items: Gan Di Xin, an oral medication for cough and expectorant relief; Qilian Shan Licorice Extract, serving as a raw material for pharmaceutical firms to produce conventional licorice tablets; and Qilian Shan licorice liquid extract, a key ingredient utilized by medical preparers for crafting compound licorice oral solutions. BGM also provides Qilian Shan oxytetracycline tablets, formulated to prevent and treat a range of ailments in poultry (chickens, turkeys), livestock (cattle, swine), and humans, in addition to Qilian Shan oxytetracycline APIs for use by pharmaceutical manufacturers.
How they make money
BGM Group Ltd. operates as a holding company that generates revenue through its biopharmaceutical division, which produces and sells pharmaceutical products like oxytetracycline API and heparin sodium, and through its AI technology division, which provides AI-driven insurance solutions and intelligent robot services.
Products & services
The company produces oxytetracycline API, crude heparin sodium, and licorice preparations, while also providing AI-based insurance sales, underwriting, and claims processing services.
Brands & revenue mix
AI platform providing insurance solutions and intelligent robot services.
Separate brand revenue is not available in this research.Source
Revenue share is not unit sales or a best-seller ranking. Parent brands and included sub-brands can overlap; do not add overlapping rows.
Product / operating segments
No reconciled product or operating-segment revenue breakdown is available for the current research period. Company-wide revenue remains separate from segment disclosure.
Geographic revenue
No reconciled geographic revenue breakdown was confirmed for the current research period.
Customer types
Customer concentration
No quantified customer-concentration disclosure is available in the current saved research.
Suppliers, materials & equipment
- Raw material suppliers — The company relies on various third-party suppliers for raw materials used in the production of its pharmaceutical products.Source
Strengths
- Integration of AI-assisted decision-making into manufacturing processesSource
Wall Street Score
Overall investment score · Quality, value, risk and opportunity
15
Poor
View category scores →
Company Quality
How good is the actual business—regardless of today’s stock price?
32
Poor
Financial Strength
27
Business Quality / Moat
8
Management
40
Growth Quality
86
Risk / Durability
15
Uses financial strength, moat, management, growth quality and durability. It excludes share price, P/E, market cap, intrinsic value and margin of safety.
Model Outlook
12-month model · What does the model think happens next?
Outperformance analysis is not currently available.
Reverse-split / listing-compliance risk: HIGH
This is a risk signal, not a prediction. It is separate from Wall Street Score and does not change the company score. It looks for listing-pressure signals such as prolonged Nasdaq trading below $1, very low share price, micro-cap size, negative free cash flow, and verified recent reverse splits.
Risk indicator: 60/100
WSS View
The quick read
The overall Wall Street Score is low across its combined quality, valuation and risk inputs. This can reflect an expensive share price, business weaknesses, or both; check Company Quality and the category breakdown before drawing a conclusion.
A current Opportunity Score is not available.
The 12-month model outlook is not currently available.
- •Asset quality scores strongly
- •Share split detected
- •Material dilution — approximately 5167.1% share-count growth
- •MAJOR RED FLAG: Reverse split proposed / authorized
- •Valuation is a weaker part of the current profile
- •Revenue fundamentals are weak
Company-specific research
Questions worth answering for BGM
These questions are generated from this company's current financial and score data so the page adds context instead of treating the headline score as a stand-alone conclusion.
- •Can BGM maintain its current revenue growth rate and improve the amount of that revenue that turns into earnings and cash?
- •How long can BGM fund negative free cash flow using its current cash position before it may need more debt or new shares?
- •How is BGM likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
- •What specifically needs to improve for BGM to reach sustainable profitability?
- •What future growth or profitability would be needed to justify BGM's current valuation?
Essential Investment Snapshot
Wall Street Score
15
Market Cap
$110.5M
P/E Ratio
-1.9
EPS
$-0.13
52-Week High
$10.57
52-Week Low
$0.23
Beta
1.81
Shares Outstanding
380.6M
Total Revenue
$74.8M
Total Debt
$1.2M
Dividend
No current dividend
Liquidation Value / Share
$1.05
Momentum & Volatility Signals
Two different market-behavior signals. Momentum measures direction and trend strength. Volatility measures how large and unstable the price moves are, regardless of direction.
Neutral / mixed momentum
Extreme movement
A high momentum score means price has been trending upward with confirming short- and medium-term strength. A low score means downward or weakening momentum.
A high volatility score means larger, less stable price swings. It can happen while a stock is rising or falling, so high volatility is not automatically bullish or bearish.
Important: the volatility score above is based on realized price volatility. Implied volatility (IV) comes from options prices and represents the market's expected future movement. Wall Street Score will keep IV separate and will only display it when a verified options-chain feed is available.
Notices for BGM
Detected from reported data — verify before acting.Share split detected
A recent SEC filing references a reverse stock split/share consolidation. Repeated reverse splits receive progressively harsher score ceilings.
Supporting sourceMaterial dilution — approximately 5167.1% share-count growth
Shares outstanding increased approximately 5167.1% across stored score snapshots. This is material dilution and is applying a Wall Street Score ceiling of 15.
MAJOR RED FLAG: Reverse split proposed / authorized
A recent SEC filing discusses authorization, approval, or a proposal for a reverse stock split. This is treated as a major distress/listing-risk signal and caps Wall Street Score below 30 while pending.
Supporting filingDividend history reported
Dividend payments are recorded. Review the dates and regular/special classification below; past payments do not guarantee future dividends.
Community Sentiment
0 active · 0 total callsNo personal call yet on BGM.
Potential upside factors
- +Growth opportunities may come from revenue expansion, margin improvement, new products, market-share gains, and stronger cash flow.
- +Integration of AI-assisted decision-making into manufacturing processes.
Potential downside factors
- −Key risks may include competition, margin pressure, debt levels, valuation risk, and changes in demand within the Drug Manufacturers - Specialty & Generic industry.
- −Reliance on VIE agreements for operations in the PRC.
- −Regulatory risks associated with operating in the pharmaceutical industry in China.
- −Shares outstanding increased approximately 5167.1% across stored score snapshots. This is material dilution and is applying a Wall Street Score ceiling of 15.
These research factors come from saved company research and financial data, not community votes. They are starting points to verify against filings, not buy or sell recommendations.
Create a free account to make a call.
Scores
Click any score for full breakdownWas this stock page easy to understand?
One click helps us improve the research experience. This is not tied to an investment decision.
Score Changes
5 historical score records availablePrevious Score
29
Sep 9, 2026
Change
-14.2
points
Current Score
15
Oct 1, 2026
Category Changes
BGM decreased 14.2 points because some fundamentals weakened.
Projected Score
Projected Score
17
Projected Change
+2.0 points
Preliminary comparable-period financial changes suggest improvement of approximately 2.0 points. This is a projected estimate, not the official WallStreetScore.
Price vs. Value
Valuation unavailableCurrent Price
$8.71
Model Intrinsic Value
—
Difference
—
Margin of Safety
—
Intrinsic value is not currently available for this stock, so valuation can't be calculated.
Financial Charts
Revenue
Additional Metrics
Operating Cash Flow
Total Debt
Total Assets
Net Margin %
Large reported revenue change: +51.1%
Revenue changed sharply from 2024 to 2025. This can reflect a real business change, acquisition, divestiture, discontinued operations, restatement, or reporting-basis change. Compare the underlying filing before treating it as normal growth or decline.
TTM may combine quarters from before and after the event, so its trend can also be distorted.
Free includes 3 annual periods plus available TTM; Premium includes up to 10 annual periods. History depends on available company filings. Swipe the table horizontally to see older periods. A dash means unavailable, not zero.
| Line Item | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $47.9M | $37.9M | $25.1M | $46.5M | ···· | ···· | ···· | ···· | ···· | ···· |
| Cost of Revenue | $41.8M | $33.1M | $21.0M | $44.7M | ···· | ···· | ···· | ···· | ···· | ···· |
| Gross Profit | $6.1M | $4.8M | $4.1M | $1.8M | ···· | ···· | ···· | ···· | ···· | ···· |
| Research & Development | $387K | $673K | $1.4M | $568K | ···· | ···· | ···· | ···· | ···· | ···· |
| SG&A Expenses | $17.0M | $16.8M | $3.3M | $3.8M | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Expenses | $17.4M | $17.4M | $4.7M | $4.4M | ···· | ···· | ···· | ···· | ···· | ···· |
| EBITDA | -$9.2M | -$11.1M | $880K | -$1.3M | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Income | -$11.2M | -$12.6M | -$564K | -$2.6M | ···· | ···· | ···· | ···· | ···· | ···· |
| Interest Expense | $11K | $0.00 | $640K | $0.00 | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Before Tax | -$16.8M | -$19.9M | -$2.1M | -$7.9M | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Tax Expense | $4.8M | $278K | -$620K | $219K | ···· | ···· | ···· | ···· | ···· | ···· |
| Net Income | -$21.2M | -$19.9M | -$1.4M | -$7.8M | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic EPS | $-0.18 | $-0.18 | $-0.20 | $-1.08 | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic Shares | 186M | 113M | 7.23M | 7.23M | ···· | ···· | ···· | ···· | ···· | ···· |
| Diluted Shares | 186M | 113M | 7.23M | 7.23M | ···· | ···· | ···· | ···· | ···· | ···· |
Earnings Summary
Revenue
$24.3M
Estimate unavailable.
Revenue Beat/Miss
Not available (no estimate stored)
EPS
-$0.01
Estimate unavailable.
EPS Beat/Miss
Not available (no estimate stored)
Debt Change
-34.1%
Cash Change
+19.3%
Margin Change
-2.6 pp
Debt and cash show percentage changes versus the comparison period; margin shows the change in percentage points (pp). These are company-wide changes, not per-share amounts.
Financial Changes Since Prior Period
What Improved
- Cash position grew
- Debt reduced
What Weakened
- Margins contracted
Potential Score Impact
Positive indicators included revenue growth, cash levels, debt levels. Pressure indicators included EPS growth, net income margin. These factors may support or pressure the Revenue, Management, Financial, and Debt categories; this summary does not claim that the stored scores changed.
Stored Earnings Analysis
Revenue increased 69.8%. EPS declined 58.5%. Cash increased 19.3%. Total debt declined 34.1%. Net income margin declined by 2.6 percentage points.
Earnings-Call Transcript
Earnings-call transcript analysis is not currently available.
These results may influence future scores when the next evaluation is completed.
Insider Activity
Guru / Smart Money
Guru Score
Smart Money
Number of Gurus
Total Guru Value
Avg Portfolio Weight
Largest Holder
Largest Holder %
New Positions
Increased Positions
Reduced Positions
Exited Positions
Net Guru Sentiment
Short Interest
Dividend History
Log in to view dividend history.
Conservative Projected Values
3 Years
$———.——
5 Years
$———.——
10 Years
$———.——
Conservative Projection Rate
——%
Conservative Projected Values — price projections derived from actual 10-year adjusted historical returns, conservatively adjusted and capped at 8% annually. These are distinct from the Outperformance Model Score and WallStreetScore.
Conservative Projected Values
Premium unlocks the 3-year, 5-year, and 10-year conservative projected values with full calculation breakdowns based on actual historical returns.
Start 7-Day Free TrialHistorical Outperformance Record
Premium includes stored forecasts and any available evaluated results. Completed results, win rates and calibrated probabilities are shown only when supported records exist; access does not create historical outcomes.
Start 7-Day Free TrialHistorical Trends
5 historical recordsHistorical Score Chart
3 of 5 records shownWall Street Score
Debt Score
Revenue Score
Asset Score
Capital Score
Management Score
Moat Score
Valuation Score
Buffett Score
Intrinsic Value
Value Reference
Margin of Safety %
Related Companies
Drug Manufacturers - Specialty & GenericRumor Mill · BGM
Corporate developments & opportunities
No reviewed developments match this filter.
Evidence credibility is not a forecast of stock performance. Rumor Mill is separate from the WSS score.
Related Stock Research
Continue researching this company with related Wall Street Score rankings and investing guides.
Score Alerts
Premium unlocks alerts when a score rises, falls, or reaches your target price.
Start 7-Day Free TrialPortfolio Score
Premium unlocks portfolio scoring, strongest and weakest holdings, and overall margin of safety.
Start 7-Day Free Trial